SAHPRA has released a statement confirming that it has registered the Johnson & Johnson vaccine, further noting how it should be administered and some of the side effects.
The South African Health Products Regulatory Authority (SAHPRA) took to Twitter on Tuesday, 6 April 2021, to endorse a statement confirming its registration of the Johnson & Johnson vaccine, known as Janssen. The vaccine is believed to be the first one that has been registered by SAHPRA, following the announcement of the vaccine being the first to be manufactured locally at the Aspen Pharmacare facility.
SAHPRA Chief Executive Officer (CEO), Boitumelo Semete-Makokotlela was quoted as saying, “The authorisation is, however, subject to a number of conditions which include that the vaccine is supplied and administered in accordance with the National Department of Health COVID-19 vaccination plan and applicable guidelines.”
Additionally, the statement noted, “The Janssen is administered as a single dose by intramuscular injection to individuals 18 years and older. According to SAHPRA, the side effects as outlined in the clinical trial evidence submitted by the applicant were usually mild or moderate and cleared within a few days after vaccination.”
See the post below.
[Read] The South African Health Products Regulatory Authority (SAHPRA)) has registered the #COVID19 Johnson & Johnson vaccine, known as Janssen, with conditions @SAHPRA1 https://t.co/Y7E0R38InX @HealthZA @DrZweliMkhize pic.twitter.com/z2oDTKIJzD
— @SAgovnews (@SAgovnews) April 6, 2021